[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591176":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":51,"collaborators":19,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":19,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":19,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":76,"whyStopped":19,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Tang-Du Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Chest wall reconstruction","EXPERIMENTAL","Participants underwent extended resection of chest wall tumors followed by chest wall reconstruction using biodegradable polycaprolactone (PCL) 3D-printed rib implants.",[13],"Device: Chest wall reconstruction",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DEVICE","Extended resection of chest wall tumors with subsequent biodegradable polycaprolactone (PCL) 3D-printed rib prosthetic reconstruction",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Xiaolong Yan","CONTACT","+86 15991269383","yanxiaolong@fmmu.edu.cn",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Lei Wang","+86 15093198361","tuodi1986@126.com",[31],{"facility":32,"status":19,"city":33,"state":34,"zip":19,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Tangdu Hospitial","Xi'an","Shaanxi","China","CN",{"type":38,"coordinates":39},"Point",[40,41],108.92861,34.25833,{"lat":41,"lon":40},[44,48,50],{"name":45,"role":23,"phone":46,"phoneExt":19,"email":47},"Xing Li","+86 02984777551","tangduec@126.com",{"name":22,"role":49,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"name":27,"role":49,"phone":19,"phoneExt":19,"email":19},{"type":52,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100591176","clinical-trial-on-the-efficacy-and-safety-of-biodegradable-3d-printed-implants-in-chest-wall-reconstruction-surgery-100591176",false,"NCT06977022","Clinical Trial on the Efficacy and Safety of Biodegradable 3D-Printed Implants in Chest Wall Reconstruction Surgery","Clinical Trial on the Efficacy and Safety of Biodegradable 3D-Printed Implants in Chest Wall Reconstruction Surgery: A Prospective, Single-Arm Phase Il Study","Inclusion Criteria:\n\n* Patients who meet all of the following criteria are eligible to participate in the study:\n\n  1. Aged 18-70 years;\n  2. No gender restriction;\n  3. ECOG Performance Status 0-1;\n  4. Chest CT-confirmed chest wall-originating tumor;\n  5. Histologically\u002Fcytologically confirmed primary or metastatic chest wall tumor;\n  6. Anticipated intraoperative anterolateral chest wall defect diameter 5-10 cm (maximum) or costal arch reconstruction required (investigator-assessed);\n  7. Scheduled for prosthetic chest wall reconstruction;\n  8. No prior chest wall reconstruction surgery;\n  9. Willing to provide written informed consent and comply with follow-up visits and protocol requirements.\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria are ineligible for this study:\n\n  1. Patients with posterior chest wall defects;\n  2. Uncontrolled underlying medical conditions or contraindications to general anesthesia;\n  3. Pregnant or lactating women;\n  4. Concurrent severe comorbidities that may interfere with study evaluations, including: Severe hepatic, cardiac, or renal diseases; Active malignancies (other than the indicated chest wall tumor); Alcohol use disorder\n  5. lnability to provide reliable symptom reporting due to:P sychiatric disorders, Severe neurosis, Non-compliance with trial requirements\n  6. Women of childbearing potential\\* and their partners unwilling to use effective contraception;\n  7. Prior history of chest wall reconstruction surgery;\n  8. Active uncontrolled bacterial, fungal, or viral infections;\n  9. Participation in other clinical trials within 3 months prior to enrollment;\n  10. Any other conditions deemedunsuitable by the investigator","ALL","18 Years","70 Years",{"count":64,"type":65},20,"ESTIMATED","INTERVENTIONAL",[68],"NA","This project focuses on patients with chest wall tumors who are expected to have a maximum intraoperative anterolateral chest wall defect diameter of 5-10 cm and require chest wall reconstruction with rib implants. It aims to evaluate the efficacy and safety of biodegradable 3D-printed implants in chest wall reconstruction surgery, providing a superior reconstruction strategy for patients with tumor-induced chest wall defects.",[71],"Chest Wall Tumor",[73,74,75],"PCL Implant","Chest Wall Reconstruction","3D Printing Technology","NOT_YET_RECRUITING","2025-05-10",{"date":79,"type":80},"2025-05-16","ACTUAL",{"date":82,"type":65},"2025-05",{"date":84,"type":65},"2028-05",{"name":5,"class":6},1]